RxDoctor Payments Data

Morgan Schubbe, MD

Urology · Neenah, WINPI 1821447418

Payments from drug & device makers

$2,144in general payments, 2019–2025

Across 56 payments — averaging $38.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Sumitomo Pharma America, Inc.$148
  • Urogen Pharma, Inc.$136
  • Intuitive Surgical$134
  • Immunitybio, Inc.$104
  • Axonics, Inc.$93
  • plus $446 from 16 others

What the payments were for

  • Food & beverage$2,144100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,144 in reported general payments places this provider in the 65th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$218,952
Medicare patients
342
Services billed
4,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron75$52,500
GemtesaVibegron85$41,934
ElmironPentosan Polysulfate Sodium11$12,979
Mirabegron ErMirabegron13$5,098
Tamsulosin Hcl281$3,812
Estradiol43$2,838
Solifenacin Succinate63$2,365
Finasteride145$1,880
Oxybutynin Chloride ErOxybutynin Chloride114$897
NitrofurantoinNitrofurantoin Macrocrystal18$535
Trospium Chloride11$515
Trimethoprim18$447
Testosterone Cypionate25$327
Cephalexin70$280
Terazosin Hcl23$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$51$52,50075 claims
Sumitomo Pharma America, Inc.Gemtesa$148$41,93485 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 215 urology providers in Wisconsin.

Other urology in Neenah

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →